February 27, 2018 6:07pm
After opening positive, traveling in the wilderness of uncertainty to close with a downside advance/decline line (A/DL) of 15/24
While the sector re-tests lows for the umpteenth time; it’s not a question of sentiment, it still slurps of momentum
If you had been subscribing, today’s events would be an afterthought as you had been informed pre-open
Pre-open indication results: 2 hits and 5 miss (I’m early in my mind)
Out and about: MiMedx Group (MDXG -$0.08) slippage is slowing with 7.92 M shares traded <3 month average = 2.93 M shares> while under federal investigation related to business practices to close at $7.27 after yesterday’s $7.35.
Review my daily “Sudoku” of indicators, factors, trend lines, advance/decline lines of 40 covered companies, pre-open indicator results, volatility and analytics of the % count of decliners versus gainers with a few surprises in the shifting sands of appreciation or depreciation
Tuesday’s results have implications to Wednesday’s sector activity as a daily report may say little or a lot and it serves as insurance that all indications are being examined and evaluated!
Henry’omics:
From the pre-open’s newsletter, “…risk grows in share pricing’s upside as I had stated, “There is a sense that … yesterday’s move to the upside was overdue yet would contribute to a decline in the ensuing sessions!” Volatility matters when gains outstrip the fundamentals and technicals; the sector may come to understand its vulnerabilities or maybe not although the inevitable is the downside.”
We’ve seeing weakness slip back into the scene – it has been behind the curtain the whole time … as momentum sent strength to the downside.
It was coming as algorithms were percolating and infecting the upside!
I saw it …
The advance/decline line scenario of 40 SCGT & RT covered companies:
· The open was positive with an A/DL of 18/16 and 6 flat ;
· The 10:30 a.m. shuffled negative the A/DL to 15/21 and 4 flats;
· The mid-day was negative with an A/DL of 14/23 and 3 flat;
· The close was negative with an A/DL of 15/24 and 1 flat;
Pre-open indication results: 2 hits and 5 miss
· AxoGen (AXGN) closed up +$1.70 – miss;
· bluebird bio (BLUE) closed up +$2.00 – miss;
· Fate Therapeutics (FATE) closed down -$0.56 – hit;
· Caladrius Bioscience (CLBS) closed up +$0.22 – miss;
· Mesoblast (MESO) closed down - $0.22 – hit;
· MiMedx (MDXG) closed down -$0.08 – miss;
· Vericel (VCEL) closed up +$0.15 – miss;
The shifting sands of appreciation and depreciation:
The come-back sector stocks: BLUE (+$2.00 after Monday’s-$4.90), ADVM (+$0.15 after -$0.30) and ATHX (+$0.06 after -$0.02)
Surprised: CLBS (+$0.22 after +$0.28),
Still on the high wire: AXGN (+$1.70) and VCEL (+$0.15 after Monday’s+$0.80)
While some downers stay down: AGTC (-$0.10 after Monday’s $0.00), AST (-$0.05 after+$0.05), ADRO (-$0.25 after -$0.05), CAPR (-$0.05 after +$0.01), FATE (-$0.56 after +0.30),
The non-gift that keeps on dipping: HSGX (-$0.02 after +$0.03), ONVO (-$0.03 after +$0.04), VSTM (-$0.01 after +$0.01), CLLS (-$0.50 after -$0.20),
Not surprised by: BLCM (+$0.04 after Monday’s +$0.25), MESO (-$0.42), OSIR (-$0.22 after -$0.45), QURE (-$0.21 after +$0.21) and STML (-$0.55 after -$0.20),
Trading games: BSTG (+$0.01), FCSC (+$0.03), KOOL (-$0.01 – on news) and BCLI (+$0.02) and NWBO ($0.002),
MY working trend lines:
… The greatest volume to the downside: MDXG, SGMO, ONCE, XON and ONVO
… Upside volume was weighted to: JUNO, CYTX, ADVM, VCEL and PSTI
… Biggest $ downside: ONCE (-$1.60), SGMO (-$1.50), FATE (-$0.56), STML (-$0.55) and CLLS (-$0.50)
… Largest $ upside: BLUE (+$2.00), AXGN (+$1.70), RGNX (+0.53), CLBS (+$0.22) and ADVM (+$0.15)
… Flat: RENE.L
Daily analytics:
U.S. stock-market indexes closed sharply lower Tuesday after Federal Reserve Chairman Jerome Powell highlighted the strengthening economy during his congressional testimony, but investors grew jittery that that improvement may prompt the central bank to be more aggressive in tightening monetary policy.
· The Dow tumbled 299.24 points, or 1.2%, to 25,410.03.
· The S&P 500 index fell 35.32 points, or 1.3%, to 2,744.28.
· The NASDAQ declined 91.11 points, or 1.2%, to 7,330.35
The CBOE Volatility Index (VIX) widely considered the best gauge of fear in the market,
- Tuesday traded at 18.59, up +17.66% …
· Monday traded at 15.80, down -4.18% …
· Friday traded at 16.64, down -11.11% …
· Thursday traded at 18.72, down -6.49% …
· Wednesday traded at 20.22, down -2.82% …
· Last Tuesday traded at 20.60, up +5.86% …
The iShares Russell 2000 (IWM) indicated:
· Tuesday was down -1.45%
· Monday +0.64%
· Friday +1.30%
· Thursday -0.15%
· Wednesday +0.09%
· Last Tuesday -0.83%
The iShares NASDAQ Biotechnology (IBB) indicated:
· Tuesday was down -1.25%
· Monday +0.73%
· Friday +2.08%
· Thursday -0.61%
· Wednesday -0.16%
· Last Tuesday -1.01%
The count - decliners versus gainers:
……. look at the differences in decliners:
· Tuesday’s decliners ranged from -0.31% <VSTM -$0.01> to -6.01%% <SGMO -$1.50> in 24 equities;
· Monday’s decliners ranged from -0.51% <RENE.L -$0.50> to -6.13% <MDXG -$0.48> in 17 equities;
· Friday’s decliners ranged from -0.34% <CLLS -$0.11> to -11.82% <MDXG -$1.05> in 17 equities;
· Thursday’s decliners ranged from -0.09% <JUNO -$0.08> to -8% <FCSC -$0.053> in 10 equities;
· Wednesday’s decliners ranged from -0.15% <BSTG -$0.00> to -10.63% <RENE.L> in 13 equities;
· Last Tuesday’s decliners ranged from -0.14% <JUNO -$0.12> to -39.53% <MDXG -$5.72> in 26 equities;
Versus
… Look at the percentage’s (%) and spreads …
· Tuesday’s gainers ranged from +0.03% <JUNO +$0.03> to +5.84% <PSTI +$0.08> in 15 equities;
· Monday’s gainers ranged from +0.02% <JUNO +$0.02> to +17.93% <MESO +$1.11> in 20 equities;
· Friday’s gainers ranged from +0.02% <JUN) +$0.02> to +11.15% <FATE +$1.18> in 21 equities;
· Thursday’s gainers ranged from +0.15% <CLLS +$0.05> to +14.41% <SGMO +$3.20> in 28 equities;
· Wednesday’s gainers ranged from +0.08% <XON +0.01> to +15.49% <FATE +$1.42> in 24 equities;
· Last Tuesday’s gainers ranged from +0.39% <FCSC +$0.0026> to +4.70% <BLCM +$0.31> in 12 equities;
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
